ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling-Reference-Cited by-同舟云学术

ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling

Published:2017-03-24 Issue:1 Volume:18 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Vesel M.,Rapp J.,Feller D.,Kiss E.,Jaromi L.,Meggyes M.,Miskei G.,Duga B.,Smuk G.,Laszlo T.,Karner I.,Pongracz J.E.

Funder

European Union and the State of Hungary, co-financed by the European Social Fund in the framework ‘National Excellence Program’

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s12931-017-0537-6.pdf

Reference54 articles.

1. Wangari-Talbot J, Hopper-Borge E. Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. J. Can. Res. Updates. 2013 [cited 19 Sep 2016];2:265–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24634705

2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. [cited 19 Sep 2016];62:10–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22237781

3. Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus PE, Sorensen JB, et al. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann. Oncol. Oxford University Press; 2011 [cited 19 Sep 2016];22:1973–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21727198

4. Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann. Oncol.2014 [cited 19 Sep 2016];25:1462–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24562446

5. Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front. Oncol. 2014 [cited 19 Sep 2016];4:204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25157335

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer;Journal of Clinical and Experimental Hepatology;2024-09

2. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer;Journal of Experimental & Clinical Cancer Research;2024-08-07

3. Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients;International Journal of Molecular Sciences;2024-08-04

4. Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy;Drug Delivery and Translational Research;2024-07-22

5. ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure;Biomedicine & Pharmacotherapy;2024-06